Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine

PLoS Pathogens

Volumn 9, Issue 5, 2013, Pages

  Blaney, Joseph E ^a   Marzi, Andrea ^b   Willet, Mallory ^c   Papaneri, Amy B ^a   Wirblich, Christoph ^c   Feldmann, Friederike ^b   Holbrook, Michael ^a   Jahrling, Peter ^a   Feldmann, Heinz ^b   Schnell, Matthias J ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RABIES VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIMATE; PROTECTION; RABIES VIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFETY; VACCINATION; VIRUS EXPRESSION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNOGLOBULIN G; MACACA MULATTA; MALE; MICE; RABIES VACCINES; RABIES VIRUS; VIRAL MATRIX PROTEINS;

ANIMALIA; EBOLA VIRUS; PRIMATES; RABIES VIRUS;

EID: 84878520300     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003389     Document Type: Article

References (39)

1. Sanchez A, Geisbert TW, Feldmann H (2007) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields virology, 5th ed. Philadelphia, PA.: Lippincott Williams & Wilkins. pp. 1409-1448.
2. Geisbert TW, Bausch DG, Feldmann H, (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20: 344-357.
3. Bradfute SB, Dye JM Jr, Bavari S, (2011) Filovirus vaccines. Human vaccines 7: 701-711.
4. Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL, (2010) Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 399: 290-298.
5. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 6: e1000904.
6. Sun Y, Carrion R Jr, Ye L, Wen Z, Ro YT, et al. (2009) Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383: 12-21.
7. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 Suppl 2: S430-437.
8. Sullivan NJ, Martin JE, Graham BS, Nabel GJ, (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7: 393-400.
9. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, et al. (2012) Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Science translational medicine 4: 158ra146.
10. Qiu X, Audet J, Wong G, Pillet S, Bello A, et al. (2012) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Science translational medicine 4: 138ra181.
11. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proceedings of the National Academy of Sciences of the United States of America 109: 5034-5039.
12. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, et al. (2013) Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A [epub ahead of print] doi: 10.1073/pnas.1209591110.
13. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, et al. (2011) CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nature medicine 17: 1128-1131.
14. Leroy EM, Rouquet P, Formenty P, Souquiere S, Kilbourne A, et al. (2004) Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303: 387-390.
15. Rouquet P, Froment JM, Bermejo M, Kilbourn A, Karesh W, et al. (2005) Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 11: 283-290.
16. Bermejo M, Rodriguez-Teijeiro JD, Illera G, Barroso A, Vila C, et al. (2006) Ebola outbreak killed 5000 gorillas. Science 314: 1564.
17. Mahanty S, Bray M, (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4: 487-498.
18. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, et al. (2011) Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Journal of virology 85: 10605-10616.
19. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A, (2010) The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 8: 51-61.
20. Cleaveland S, Fevre EM, Kaare M, Coleman PG, (2002) Estimating human rabies mortality in the United Republic of Tanzania from dog bite injuries. Bull World Health Organ 80: 304-310.
21. Knobel DL, du Toit JT, Bingham J, (2002) Development of a bait and baiting system for delivery of oral rabies vaccine to free-ranging African wild dogs (Lycaon pictus). J Wildl Dis 38: 352-362.
22. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, et al. (2002) Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292: 24-34.
23. McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, et al. (2001) Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 75: 4430-4434.
24. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, et al. (2003) Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol 77: 10889-10899.
25. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, et al. (2003) Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77: 237-244.
26. McGettigan JP, Sarma S, Orenstein JM, Pomerantz RJ, Schnell MJ, (2001) Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 75: 8724-8732.
27. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ, (2010) Characterization of a single-cycle rabies virus-based vaccine vector. J Virol 84: 2820-2831.
28. McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, et al. (2004) Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J Virol 78: 13455-13459.
29. Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, et al. (2006) Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353: 344-56.
30. Vos A, Neubert A, Aylan O, Schuster P, Pommerening E, et al. (1999) An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol Infect 123: 165-175.
31. Vos A, Pommerening E, Neubert L, Kachel S, Neubert A, (2002) Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis). J Wildl Dis 38: 428-431.
32. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, et al. (2005) Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 331: 82-93.
33. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, et al. (2000) Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78: 693-698.
34. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y, (2003) Antibody-dependent enhancement of Ebola virus infection. J Virol 77: 7539-7544.
35. Shearer MH, Dark RD, Chodosh J, Kennedy RC, (1999) Comparison and characterization of immunoglobulin G subclasses among primate species. Clin Diagn Lab Immunol 6: 953-958.
36. Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, et al. (2012) A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 434: 18-26.
37. Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, et al. (2012) Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 30: 6136-6141.
38. Fuse S, Molloy MJ, Usherwood EJ, (2008) Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions. Crit Rev Immunol 28: 159-183.
39. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, et al. (2008) Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 26: 6405-6414.